This assay detects human autoantibodies against neuronal antigens to aid the diagnosis of multiple neurological conditions. It is performed on tissue substrates, allowing identification of antibody reactivities to distinct components of nervous tissue.
In paraneoplastic neurological syndromes (PNS), antibody testing is recommended using at least two independent methods. For high-risk phenotypes, testing combines indirect immunofluorescence (IIF) on tissue and immunoblot; for intermediate- and low-risk phenotypes, testing combines IIF on tissue and cell-based assays (transfected cells).
Depending on the case, tissues used for IIF include cerebellum, hippocampus, intestine, and/or nerve. In addition, in-house immunohistochemistry (home-made tests) can be performed for further work-up.
Serum, EDTA plasma, heparin plasma, citrate plasma, CSF
IFA tissue, IHC*
*only for in-depth analysis
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.